| | ID | Study
(reference) | GI AE§ | GLP-1 (n) | Control (n) | Background
therapy | Trial
duration
(week) | Age
(year) | T2DM
course
(year) | HbA1c0
(%) |
| | 1 |
Rosenstock et al. 2009 [28] | N, V, D | EX10BID (34) | Placebo (50) | Met | 16 | 54 | 4.9 | 8 | | 2 | Apovian et al. 2010 [29] | N, D | EX10BID (96) | Placebo (98) | Met/Su/Su+Met | 24 | 54.8 | 5.5 | 7.6 | | 3 | Barnett et al. 2007 [30] | N, V | EX10BID (138) | Insulin (138) | Met/Su | 16 | 54.9 | 7.4 | 9 | | 4 | Blevins et al. 2011 [31] | N, V, D | EX10BID (123) | EX2QW (129) | Met+/−Su+/−TZD | 24 | 55.5 | 7.0 | NR | | 5 | Bergenstal et al. 2010 [32] | N, V, D | EX10BID (160) | Pig (165)
Sitagliptin (166) | Met | 26 | 52.5 | 6 | 8.6 | | 6 | Bunck et al. 2009 [33] | N, V, D | EX10BID (36) | Insulin (33) | Met | 52 | 58.3 | 4.9 | 7.5 | | 7 | Buse et al. 2004 [34] | N, V, D | EX5BID (125), EX10BID (129) | Placebo (123) | Su | 30 | 55 | 6.3 | 8.6 | | 8 | Buse et al. 2011 [35] | N, V | EX10BID (137) | Placebo (122) | GLAR+/−CT | 30 | 59 | 12 | 8.4 | | 9 | Davies et al. 2009 [36] | N, V, D | EX10BID (118) | Insulin (116) | Met/Su/TZD | 26 | 56.5 | 8.7 | 8.6 | | 10 | DeFronzo et al. 2005 [37] | N, V, D | EX5BID (110), EX10BID (113) | Placebo (113) | Met | 30 | 53 | 5.8 | 8.2 | | 11 | DeFronzo et al. 2010 [38] | N, V, D | EX10BID (45) | Rog (45) | Met | 20 | 56 | 4.7 | 7.8 | | 12 | Diamant et al. 2010 [39] | N, V, D | EX2QW (233) | Insulin (233) | Met/Met+Su | 26 | 58 | 7.9 | 8.3 | | 13 | Drucker et al. 2008 [40] | N, V, D | EX10BID (145) | EX2QW (148) | Met+/−Su+/−TZD | 30 | 55 | 6.5 | 8.3 | | 14 | Fineman et al. 2003 [41] | N | EX10BID (81) | Placebo (28) | Met/Su | 4 | 51.9 | NR | 9.3 | | 15 | Gallwitz et al. 2011 [42] | N, V, D | EX10BID (247) | Insulin (233) | Met/Su | 26 | NR | NR | NR | | 16 | Gao et al. 2009 [43] | N, V, D | EX10BID (234) | Placebo (232) | Met/Met+Su | 16 | 54.5 | 8 | 8.3 | | 17 | Gill et al. 2010 [44] | N, V, D | EX10BID (28) | Placebo (26) | Met/Met+TZD | 12 | 55.6 | 6.5 | 7.3 | | 18 | Heine et al. 2005 [45] | N, V, D | EX10BID (282) | Insulin (267) | Met+Su | 26 | 58.9 | 9.6 | 8.2 | | 19 | Kadowaki et al. 2009 [46] | N, V, D | EX5BID (37), EX10BID (37) | Placebo (40) | Su/Bg/Su+TZD/Bg | 12 | 60.3 | 11.8 | 8 | | 20 | Kendall et al. 2005 [47] | N, V, D | EX5BID (245), EX10BID (241) | Placebo (247) | Met/Met+Su | 30 | 55.3 | 8.9 | 8.5 | | 21 | Kim et al. 2007 [48] | N, V | EX2QW (15) | Placebo (14) | Met | 15 | 54 | 5 | 8.5 | | 22 | Liutkus et al. 2010 [49] | N, V, D | EX10BID (111) | Placebo (54) | TZD/TZD+Met | 26 | 54.7 | 6.4 | 8.2 | | 23 | Moretto et al. 2008 [50] | N, V, D | EX5BID (78), EX10BID (77) | Placebo (77) | None | 24 | 54 | 2 | 7.8 | | 24 | Nauck et al. 2007 [51] | N, V, D | EX10BID (253) | Insulin (248) | Met/Su | 52 | 58.5 | 9.9 | 8.6 | | 25 | NCT00577824, 2009 [52] | N, V, D | EX5BID (72), EX10BID (72) | Placebo (35) | None | 24 | 58.4 | NR | NR | | 26 | Poon et al. 2005 [53] | N | EX5BID (31), EX10BID (31) | Placebo (33) | Met/none | 4 | 52.9 | 3.9 | 7.6 | | 27 | Zinman et al. 2007 [54] | N, V, D | EX10BID (121) | Placebo (112) | TZD/TZD+Met | 16 | 56 | 8 | 7.9 | | 28 | Buse et al. 2009
(LEAD6) [55] | N, V, D | LIR1.8 (235) | EX10BID (232) | Met/Su/Met+Su | 26 | 56.7 | 8.2 | 8.3 | | 29 | Garber et al. 2009 (LEAD3) [56] | N, V, D | LIR1.2 (251),
LIR1.8 (246) | Su (248) | None | 104 | 53 | 5.4 | 8.3 | | 30 | Marre et al. 2009 (LEAD1) [57] | N, V, D | LIR1.2 (228),
LIR1.8 (234) | Placebo (114) Rog (232) | Glimepride | 26 | 56.1 | 6.5 | 8.4 | | 31 | Nauck et al. 2009 (LEAD2) [58] | N, V, D | LIR0.6 (242),
LIR1.2 (240),
LIR1.8 (242) | Placebo (121) Su (242) | Met | 104 | 57 | 7.4 | 8.4 | | 32 | Pratley et al. 2011 [59] | N, V, D | LIR1.2 (221),
LIR1.8 (218) | Sitagliptin (219) | Met | 52 | 55.3 | 6.2 | 8.4 | | 33 | Russell-Jones et al.
2009 (LEAD5) [60] | V, D | LIR1.8 (230) | Placebo (114) Insulin (232) | Met & Glimepride | 26 | 57.6 | 9.4 | 8.3 | | 34 | Yang et al. 2011 [61] | N, V | LIR0.6 (231),
LIR1.2 (233),
LIR1.8 (233) | Su (231) | Met | 16 | 53.3 | 7.5 | 8.5 | | 35 | Zinman et al. 2009 (LEAD4) [62] | N, V | LIR1.2 (178) | LIR1.8 (178) | Met/Rog | 26 | 55 | 9 | 8.5 |
|
|
